Leading distributor of pharmaceuticals and medical supplies
) recently revealed that, for the sixth straight year, it will
provide grants to aid Puerto Rican, Canadian and U.S. healthcare
facilities to improve the quality and efficiency of patient care.
Till date, the Cardinal Health Foundation has handed out 190
grants aggregating over $5.25 million.
AMERISOURCEBRGN (ABC): Free Stock Analysis
CARDINAL HEALTH (CAH): Free Stock Analysis
MCKESSON CORP (MCK): Free Stock Analysis
To read this article on Zacks.com click here.
Applicants to the Cardinal Health Foundation E3 Grant Program are
being asked to provide requests either for efforts that will
enhance medication safety (especially as patients are shifted
from inpatient facilities to their residence) or for endeavors
that will enhance operating room precautionary measures in line
with WHO guidelines.
Grant recipients engaged in medication safety efforts will be
supported by specialists from the Cardinal Health Pharmacy
Solutions Team. Recipients involved with surgical problems will
be guided by experts from the Association of periOperative
Registered Nurses (AORN).
Prospective grant applicants may consult the AORN site for ideas
regarding better practices. The Cardinal Health community site
provides briefs of past proposals which were accepted.
As per concerned inpatient facilities, past grants have helped
them to cut down on their mistakes. In fact, previous grant
recipients have provided a return of 11 times the original
investment by Cardinal Health Foundation.
The Cardinal Health Foundation will host two web sessions on the
subject on October 23 and October 26, 2012. Applicants must
submit their proposals at the Cardinal Health community website
by December 7, 2012.
Cardinal Health is ranked among Fortune 500 companies. With over
$100 billion in annual sales, Cardinal Health remains one of the
largest distributors of pharmaceuticals and medical supplies in
the U.S. The company's diversified product portfolio may partly
insulate it from the current economic uncertainty.
The company stands to gain from the gradual shift in mix from
bulk to the higher-margin non-bulk sector of the Pharmaceutical
segment. It is also riding the generic wave. Overall, Cardinal
benefits from a spate of tuck-in acquisitions and capital
However, the company faces tough competition across all business
segments, which may continue to pressure pricing and margins. Its
major competitors in the pharmaceutical supply chain segment
). We have a long-term Neutral recommendation on Cardinal.